Autologous attenuated T-cell vaccine (Tovaxin®) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies

Clinical Immunology

Volumn 131, Issue 2, 2009, Pages 202-215

  Loftus, B ^a   Newsom, B ^b   Montgomery, M ^b   Von Gynz Rekowski, K ^b   Riser, M ^b   Inman, S ^b   Garces, P ^b   Rill, D ^b   Zhang, J ^c   Williams, J C ^b  

^a Bellaire High School   (United States)

^b Opexa Therapeutics   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Multiple sclerosis; ; Myelin reactive T cells; T cell vaccination;

Indexed keywords

TOVAXIN; UNCLASSIFIED DRUG; VACCINE;

ACNE; ARTICLE; BLOOD DISEASE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DENTAL CARIES; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSESTHESIA; EYE INFECTION; FEMALE; HORDEOLUM; HUMAN; INFECTION; INFESTATION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRADIATION; LIMB PAIN; LOW DRUG DOSE; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NAIL DISEASE; NEUROLOGIC DISEASE; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; RHINOPHARYNGITIS; SINUSITIS; SKIN DISEASE; STREPTOCOCCAL PHARYNGITIS; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINATION; VAGINA CANDIDIASIS; VIRUS INFECTION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFUSIONS, SUBCUTANEOUS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN BASIC PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, ATTENUATED; VACCINES, SUBUNIT;

EID: 63749125437     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.01.005     Document Type: Article

References (47)

1. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10 (1992) 153-187
2. Zhang J. Multiple sclerosis: perspectives on autoimmune pathology and prospects for therapy. In: Appel S. (Ed). Current Neurology 15 (1995), Mosby Year Book, Chicago, USA 115-155
3. Zhang J. T-cell vaccination for autoimmune diseases: immunologic lesions and clinical experience in multiple sclerosis. Expert Rev. Vaccines 1 (2002) 285-292
4. Compston A., and Sawcer S. Genetic analysis of MS. Curr. Neurol. Neurosci. Rep. 2 (2002) 259-266
5. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3 (2002) 291-301
6. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., and Brück W. Acute axonal injury in multiple sclerosis, correlation with demyelination and inflammation. Brain 123 (2000) 1174-1183
7. Ben-Nun A., Wekerle H., and Cohen I.R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11 (1981) 195-199
8. Ben-Nun A., Wekerle H., and Cohen I.R. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292 (1981) 60-61
9. Holoshitz J., Frenkel A., Ben-Nun A., and Cohen I.R. Autoimmune encephalomyelitis (EAE) mediated or prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein, vaccination is determinant specific. J. Immunol. 131 (1983) 2710-2713
10. Quintana F.J., and Cohen I.R. Anti-ergotypic immunoregulation. Scand. J. Immunol. 64 (2006) 205-210
11. Zang Y.C., Hong J., Tejada-Simon M.V., Li S., Rivera V.M., Killian J.M., and Zhang J.Z. Th2 immune regulation induced by T-cell vaccination in patients with multiple sclerosis. Eur. J. Immunol. 30 (2000) 908-913
12. Mimran A., and Cohen I.R. Regulatory T-cells in autoimmune diseases: anti-ergotypic T-cells. Int. Rev. Immunol. 24 (2005) 159-179
13. Coleman M.P., and Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 25 (2002) 532-537
14. Neumann H., Medana I.M., Bauer J., and Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25 (2002) 313-319
15. Zang Y., Li S., Rivera V.M., Hong J., Robinson R.R., Breitbach W.T., Killian J.M., and Zhang J.Z. Increased CD8+ cytotoxic T-cell responses to myelin basic protein in multiple sclerosis. J. Immunol. 172 (2004) 5120-5127
16. Traugott U., Reinherz E.L., and Raine C.S. Multiple sclerosis: distribution of T-cell subsets within active chronic lesions. Science 219 (1983) 308-310
17. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., Friese M., Schröder R., Deckert M., Schmidt S., Ravid R., and Rajewsky K. Clonal expansions of CD8+ T-cells dominate the T-cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192 (2000) 393-404
18. Jiang H., Braunstein N.S., Yu B., Winchester R., and Chess L. CD8+ T-cells control the TH phenotype of MBP-reactive CD4+ T-cells in EAE mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6301-6306
19. Najafian N., Chitnis T., Salama A.D., Zhu B., Benou C., Yuan X., Clarkson M.R., Sayegh M.H., and Khoury S.J. Regulatory functions of CD8+CD28- T-cells in an autoimmune disease model. J. Clin. Invest. 112 (2003) 1037-1048
20. Chou Y.K., Bourdette D.N., Offner H., and Vandenbark A.A. Frequency of T-cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebral fluid in multiple sclerosis. J. Neuroimmunol. 37 (1992) 105-114
21. Vandevyver C., Mertens N., van den Elsen P., Medaer R., Raus J., and Zhang J. Clonal expansion of myelin basic protein-reactive T-cells in patients with multiple sclerosis: restricted T-cell receptor V gene rearrangements and CDR3 sequence. Eur. J. Immunol. 25 (1995) 958-968
22. Zhang J., Medaer R., Stinissen P., Hafler D., and Raus J. MHC restricted depletion of human myelin basic protein-reactive T-cells by T-cell vaccination. Science 261 (1993) 1451-1454
23. Zhang J., Vandevyver C., Stinissen P., Medaer R., and Raus J. In vivo clonotypic regulation of human myelin basic protein-reactive T-cells by T-cell vaccination. J. Immunol. 155 (1995) 5868-5877
24. Lider O., Reshef T., Ben-Nun A., and Cohen I.R. Anti-idiotypic network induced by T-cell vaccination against experimental autoimmune encephalomyelitis. Science 239 (1988) 181-183
25. Zang Y.C.Q., Hong J., Rivera V.M., Killian J.M., Rivera V.M., and Zhang J.Z. Preferential recognition of hypervariable region sequence by anti-idiotypic T-cells induced by T-cell vaccination. J. Immunol, 164 (2000) 4011-4017
26. Achiron A., and Barak Y. Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study. Arch. Neurol. 57 (2000) 974-979
27. Medaer R., Stinissen P., Truyen L., Raus J., and Zhang J. Depletion of myelin-basic-protein autoreactive T-cells by T-cell vaccination: pilot clinical trial in multiple sclerosis. Lancet 346 (1995) 807-808
28. Zhang J.Z., Rivera V.M., Tejada-Simon M.V., Yang D.Y., Hong J., Li S.F., Haykal H., Killian J., and Zang Y.C.Q. T-cell vaccination in multiple sclerosis: results of a preliminary clinical trial. J. Neurol. 249 (2002) 212-218
29. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., and Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990) 183-187
30. Achiron A., Lavie G., Kishner I., Stern Y., Sarova-Pinhas I., Ben-Aharon T., Barak Y., Raz H., Lavie M., Barliya T., Faibel M., Cohen I.R., and Mandel M. T-cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin. Immunol. 113 2 (2004) 155-160
31. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sible W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 3 (1983) 227-231
32. Frohman E.M., Goodin D.S., Calabresi P.A., Corboy J.R., Coyle P.K., Filippi M., Frank J.A., Galetta S.L., Grossman R.I., Hawker K., Kachuck N.J., Lewin M.C., Phillips J.T., Racke M.K., Rivera V.M., and Stuart W.H. The utility of MRI in suspected MS: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 61 (2003) 602-611
33. Kurtzke J.F. Rating neurologic impairment in MS: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-14452
34. Hobart J., Lamping D., Fitzpatrick R., Riazi A., and Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124 (2001) 962-973
35. ICH harmonized tripartite guidelines for good clinical practice: E6(R1), June 10, 1996, (Accessed August 18, 2006, at http://www.ichorg/LOB/media/MEDIA482.pdf).
36. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human patients, (Accessed August 18, 2006, at http://www.wma.net/e/policy/b3.htm.)
37. Confavreux C. Infections and the risk of relapse in multiple sclerosis. Brain 125 (2002) 933-934
38. Buljevac D., Flach H.Z., Hop W.C.J., Hijdra D., Laman J.D., Savelkoul H.F.J., van der Meché F.G.A., van Doom P.A., and Hintzen R.Q. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125 (2002) 952-960
39. Correale J., Fiol M., and Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 67 (2006) 652-659
40. Pette M., Fujita K., Wilkinson D., Altmann D.M., Trowsdale J., Giegerich G., Hinkkanen A., Epplen J.T., Kappos L., and Wekerle H. Myelin autoreactivity in multiple sclerosis: recognition of MBP in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc. Natl. Acad. Sci. U. S. A. 76 (1990) 6962-6967
41. Lefkovits I., and Waldmann H. Limiting dilution analysis of the cells of the immune system: the clonal basis of the immune-response. Immunol. Today 5 (1984) 265-268
42. Zhang J.W., Medaer R., Hashim G.A., Chin Y., van den Berg-Loonen E., and Raus J.C. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol. 32 (1992) 330-338
43. United States Pharmacopeia USP 25. Chapter <85> Bacterial Endotoxins Test. Rockville, Maryland: The United States Pharmacopeial Convention, Inc. (2002) 1890-1893.
44. United States Pharmacopeia USP 25. Chapter <71> Sterility Tests. Rockville, Maryland: The United States Pharmacopeial Convention, Inc. (2002) 1878-1883.
45. Barcellos L.F., Oksenberg J.R., Green A.J., Bucher P., Rimmler J.b., Schmidt S., Garcia M.E., Lincoln R.R., Pericak-Vance M.A., Haines J.L., and Hauser S.L. Genetic basis for clinical expression in MS. Brain 125 (2002) 150-158
46. Wucherpfenning K.W., Allen P.M., Celada F., Cohen I.R., De Boer R., Garcia K.C., Goldstein B., Greenspan R., Hafler D., Hodgkin P., Huseby E.S., Krakauer D.C., Nemazee D., Pereison A.S., Pinilla C., Strong R.K., and Sercarz E.E. Polyspecificity of T-cell and B cell receptor recognition. Semin. Immunol. 19 4 (2007) 216-224
47. Martínez-Yélamos S., Martínez-Yélamos A., Ozaeta G.M., Casado V., Carmona O., and Arbizu T. Regression to the mean in multiple sclerosis accounts to 40% reduction in ARR. Mult. Scler. 12 6 (2006) 826-829